Vaxcyte, Inc. (NASDAQ:PCVX) Shares Bought by Franklin Resources Inc.

Franklin Resources Inc. lifted its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 13.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,786,335 shares of the company’s stock after buying an additional 324,560 shares during the period. Franklin Resources Inc. owned approximately 2.24% of Vaxcyte worth $315,162,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Riverview Trust Co acquired a new position in Vaxcyte during the 3rd quarter valued at about $27,000. Fifth Third Bancorp acquired a new position in shares of Vaxcyte during the second quarter valued at approximately $35,000. Blue Trust Inc. raised its holdings in Vaxcyte by 33.5% during the third quarter. Blue Trust Inc. now owns 371 shares of the company’s stock worth $42,000 after purchasing an additional 93 shares in the last quarter. Quest Partners LLC acquired a new stake in Vaxcyte in the second quarter worth approximately $70,000. Finally, Meeder Asset Management Inc. boosted its stake in Vaxcyte by 1,007.9% during the 3rd quarter. Meeder Asset Management Inc. now owns 698 shares of the company’s stock valued at $80,000 after purchasing an additional 635 shares in the last quarter. 96.78% of the stock is owned by institutional investors.

Insider Buying and Selling at Vaxcyte

In other Vaxcyte news, SVP Mikhail Eydelman sold 5,000 shares of Vaxcyte stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $109.27, for a total value of $546,350.00. Following the completion of the sale, the senior vice president now directly owns 28,623 shares in the company, valued at $3,127,635.21. The trade was a 14.87 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Grant Pickering sold 7,098 shares of the stock in a transaction on Monday, October 7th. The stock was sold at an average price of $109.21, for a total transaction of $775,172.58. Following the transaction, the chief executive officer now owns 138,581 shares in the company, valued at approximately $15,134,431.01. This trade represents a 4.87 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 117,830 shares of company stock worth $12,600,310. 3.10% of the stock is currently owned by company insiders.

Vaxcyte Trading Down 0.2 %

NASDAQ PCVX opened at $87.72 on Friday. Vaxcyte, Inc. has a 1 year low of $53.83 and a 1 year high of $121.06. The stock’s 50-day moving average price is $101.11 and its two-hundred day moving average price is $91.68. The company has a market cap of $10.93 billion, a PE ratio of -19.07 and a beta of 0.94.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.27. During the same quarter last year, the business posted ($0.91) EPS. Research analysts forecast that Vaxcyte, Inc. will post -4.14 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

PCVX has been the topic of a number of research reports. Jefferies Financial Group boosted their price objective on Vaxcyte from $108.00 to $129.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. Mizuho upped their price target on shares of Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a report on Tuesday, September 10th. Needham & Company LLC reaffirmed a “buy” rating and issued a $140.00 price objective on shares of Vaxcyte in a research note on Wednesday, November 6th. Bank of America boosted their target price on shares of Vaxcyte from $101.00 to $140.00 and gave the stock a “buy” rating in a report on Wednesday, September 4th. Finally, BTIG Research lifted their price target on shares of Vaxcyte from $98.00 to $160.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $147.50.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.